News

InSphero Accelerates Global Growth and US Expansion with Acquisition of PhenoVista Biosciences

Schlieren, Switzerland - May 20, 2026 Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing InSphero, the global leader in advanced 3D in vitromodels and services for drug safety and efficacy testing, today announced the acquisition of California-based...

read more

Mabylon Reports Positive Phase Ia Results in MY006 Peanut Allergy Trial and Initiates Phase Ib Patient Part of the Study; Advances Tree Pollen Allergy Program MY010 toward Clinical Development

Schlieren/Zurich, Switzerland, May 19, 2026 - Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. Mabylon also announced the initiation of dosing...

read more

CUTISS receives new patent for skin engineering technology

CUTISS has been granted a new U.S. patent. It covers automated methods and systems for producing skin grafts, including the separation of skin layers and the isolation of key cell types from a skin biopsy. The patented invention relates to a broader automated workflow for skin graft production, in which a...

read more

Lightium Selects Aras Innovator to Support Development of Photonic AI Chips

ANDOVER, Mass.--(BUSINESS WIRE)--Aras, a leading provider of digital thread solutions for product lifecycle management (PLM) and engineering AI, today announced that Lightium, a Switzerland-based startup specializing in photonic integrated circuits (PICs), has selected Aras Innovator® to establish a connected foundation for managing the complexity of its photonic chip development. Lightium selected Aras Innovator...

read more

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...

read more